Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.77 |
| ▸ | LMNA | P02545 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | TSHR | P16473 | 5/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.77 |
| ▸ | PGR | P06401 | 4/20 | 0.77 |
| ▸ | AR | P10275 | 4/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.77 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | SHBG | P04278 | 4/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | SNCA | P37840 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24102454 | 1.00 | CYP3A4 (0.77) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL5026074 | 1.00 | CYP3A4 (0.77) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL5026185 | 1.00 | CYP3A4 (0.77) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL24102479 | 1.00 | CYP3A4 (0.77) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL8814296 | 0.98 | CYP3A4 (0.80) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL6442894 | 0.91 | CYP3A4 (0.80) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL24102393 | 0.90 | CYP3A4 (0.86) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL24102394 | 0.90 | CYP3A4 (0.86) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL9664215 | 0.90 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL4617560 | 0.90 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | BIOVIE INC. | 2005-07-21 | — | — | US | claimed |
| US-8722652-B2 | Acute treatment of social phobia | PHERIN PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130172305-A1 | Acute Treatment of Social Phobia | PHERIN PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| EP-1957121-B1 | ACUTE TREATMENT OF SOCIAL PHOBIA WITH AN ANDROSTA-4,16-DIEN-3-OL STEROID | PHERIN PHARM INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8309539-B2 | Acute treatment of social phobia | PHERIN PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20070059249-A1 | Acute treatment of social phobia | PHERIN PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172305-A1 | Acute Treatment of Social Phobia | NR3C2, OR10J3, HSD3B1 | CYP3A4 707/4885LMNA 3045/4885MAPT 3713/4885 |
| US-20070059249-A1 | Acute treatment of social phobia | NR3C2, OR10J3, HSD3B1 | CYP3A4 712/4885LMNA 3032/4885MAPT 3690/4885 |
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | HSD17B7, NR5A1, HSD3B1 | CYP3A4 144/4885LMNA 4071/4885MAPT 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.